Armas Pharmaceuticals announced the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more than two years, and its return underscores Armas' commitment to providing critical medications with a focus on consistent supply and sustainability.
Lidocaine Jelly 2% is a topical anesthetic used in various medical applications, including urological and endoscopic procedures, to provide localized pain relief. Its reintroduction is expected to address a significant gap in the market and meet the needs of healthcare providers nationwide.
"Our mission at Armas Pharmaceuticals is to ensure that essential medications remain consistently available to the healthcare community," said Joe Niemi, President & CEO of Armas Pharmaceuticals. "The return of Lidocaine Jelly 2% 30mL represents our ongoing commitment to supply chain sustainability and our ability to respond to critical product needs in the market. We will continue to expand our portfolio with a focus on reliability, quality, and patient care."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!